Repurposing of the RIPK1 selective benzo[1,4]oxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitorSebastian Mandel, Stefan Knapp|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 2
Covalent targeting leads to the development of LIMK1 isoform-selective inhibitorsSebastian Mandel, Stefan Knapp|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0